Nanologica AB (FRA:4YD) E10: €-0.02 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4YD Nanologica AB FRA:4YD
45 GF Score
Price €0.03
GF Value €0.30
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Nanologica AB E10?

Nanologica AB FRA:4YD -5.39% 45 E10 is €-0.02 as of Mar. 2026. GuruFocus rates FRA:4YD with a GF Score™ of 45/100 and a GF Value™ of €0.30 (Modestly Undervalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Nanologica AB's adjusted earnings per share data for the three months ended in Mar. 2026 was €0.067. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.02 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-18), Nanologica AB's current stock price is €0.0316. Nanologica AB's E10 for the quarter that ended in Mar. 2026 was €-0.02. Nanologica AB's Shiller PE Ratio of today is .


Nanologica AB  (FRA:4YD) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Nanologica AB E10 Related Terms


Nanologica AB E10 Historical Data

* Premium members only.

The historical data trend for Nanologica AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanologica AB E10 Chart

Nanologica AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.22 -0.15

Nanologica AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.21 -0.18 -0.15 -0.02

FRA:4YD vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Nanologica AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanologica AB Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanologica AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nanologica AB's Shiller PE Ratio falls into.


FRA:4YD
45GF Score
Nanologica AB FRA:4YD
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanologica AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nanologica AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.067/133.5600*133.5600
=0.067

Current CPI (Mar. 2026) = 133.5600.

Nanologica AB Quarterly Data

per share eps CPI Adj_EPS
201606 -0.190 101.019 -0.251
201609 -0.177 101.138 -0.234
201612 -0.083 102.022 -0.109
201703 -0.139 102.022 -0.182
201706 -0.142 102.752 -0.185
201709 -0.104 103.279 -0.134
201712 -0.036 103.793 -0.046
201803 -0.106 103.962 -0.136
201806 -0.044 104.875 -0.056
201809 -0.026 105.679 -0.033
201812 -0.025 105.912 -0.032
201903 -0.017 105.886 -0.021
201906 -0.027 106.742 -0.034
201909 -0.027 107.214 -0.034
201912 -0.043 107.766 -0.053
202003 -0.035 106.563 -0.044
202006 -0.016 107.498 -0.020
202009 -0.019 107.635 -0.024
202012 -0.018 108.296 -0.022
202103 -0.026 108.360 -0.032
202106 -0.031 108.928 -0.038
202109 -0.042 110.338 -0.051
202112 -0.050 112.486 -0.059
202203 -0.051 114.825 -0.059
202206 -0.043 118.384 -0.049
202209 -0.034 122.296 -0.037
202212 -0.035 126.365 -0.037
202303 -0.028 127.042 -0.029
202306 -0.034 129.407 -0.035
202309 -0.027 130.224 -0.028
202312 -0.086 131.912 -0.087
202403 -0.039 132.205 -0.039
202406 -0.021 132.716 -0.021
202409 -0.047 132.304 -0.047
202412 -0.016 132.987 -0.016
202503 -0.013 132.825 -0.013
202506 -0.013 133.699 -0.013
202509 -0.011 133.480 -0.011
202512 -0.017 133.390 -0.017
202603 0.067 133.560 0.067

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.02 mean?
Nanologica AB (FRA:4YD) has a E10 of €-0.02 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Nanologica AB and its competitors.
Is Nanologica AB's E10 too high?
Nanologica AB's current E10 is €-0.02. Overall, Nanologica AB has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's E10 compare to VRTX and REGN?
Nanologica AB's E10 of €-0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Nanologica AB and its competitors. Nanologica AB's current E10 is €-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (FRA:4YD) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.30, compared to a current price of €0.03 — trading 89.5% below its estimated fair value. The current E10 is €-0.02. Nanologica AB's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Nanologica AB (FRA:4YD), the current E10 is €-0.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nanologica AB (FRA:4YD) Overvalued in 2026?

Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued. The current stock price of €0.03 is trading 89.5% below its estimated GF Value™ of €0.30. GuruFocus considers Nanologica AB to be Modestly Undervalued.

Key valuation signals for FRA:4YD:

  • E10: €-0.02
  • GF Value™: €0.30 vs. price of €0.03 (89.5% below fair value)
  • GF Score™: 45/100 with 9 warning signs

No single metric tells the full story. See the FRA:4YD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanologica AB Business Description

Other Exchanges NICA:Sweden
Address Forskargatan 20 G, Sodertalje, SWE, 151 36
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
45GF Score

Get the complete analysis for FRA:4YD

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price
€0.30
GF Value